Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
3.650
+0.020 (0.55%)
At close: Jul 30, 2026, 4:00 PM EDT
3.556
-0.094 (-2.59%)
After-hours: Jul 30, 2026, 7:34 PM EDT
Plus Therapeutics Revenue
Plus Therapeutics had revenue of $1.03M in the quarter ending March 31, 2026, a decrease of -2.93%. This brings the company's revenue in the last twelve months to $5.18M, down -0.46% year-over-year. In the year 2025, Plus Therapeutics had annual revenue of $5.21M, down -10.49%.
Revenue (ttm)
$5.18M
Revenue Growth
-0.46%
P/S Ratio
4.85
Revenue / Employee
$185,071
Employees
28
Market Cap
25.12M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.21M | -611.00K | -10.49% |
| Dec 31, 2024 | 5.82M | 911.00K | 18.54% |
| Dec 31, 2023 | 4.91M | 4.69M | 2,093.30% |
| Dec 31, 2022 | 224.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 303.00K | -6.70M | -95.67% |
| Dec 31, 2019 | 7.00M | 4.02M | 134.60% |
| Dec 31, 2018 | 2.98M | -739.00K | -19.85% |
| Dec 31, 2017 | 3.72M | -3.00M | -44.65% |
| Dec 31, 2016 | 6.72M | -97.00K | -1.42% |
| Dec 31, 2015 | 6.82M | 4.18M | 157.88% |
| Dec 31, 2014 | 2.65M | -2.43M | -47.87% |
| Dec 31, 2013 | 5.07M | -718.00K | -12.40% |
| Dec 31, 2012 | 5.79M | 3.78M | 187.73% |
| Dec 31, 2011 | 2.01M | -360.00K | -15.17% |
| Dec 31, 2010 | 2.37M | -6.52M | -73.32% |
| Dec 31, 2009 | 8.89M | 6.57M | 282.49% |
| Dec 31, 2008 | 2.33M | -2.93M | -55.77% |
| Dec 31, 2007 | 5.26M | -1.22M | -18.82% |
| Dec 31, 2006 | 6.48M | 6.11M | 1,645.55% |
| Dec 31, 2005 | 371.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| Evaxion | 7.53M |
| Kyntra Bio | 7.44M |
| Aligos Therapeutics | 4.71M |
| Werewolf Therapeutics | 1.14M |
| IGC Pharma | 1.11M |
| ABVC BioPharma | 797.92K |
| Actinium Pharmaceuticals | 90.00K |
PSTV News
- 2 days ago - Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference - GlobeNewsWire
- 9 days ago - Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - GlobeNewsWire
- 14 days ago - Plus Therapeutics, Genomic Testing Cooperative partner on sequencing technology - TheFly
- 14 days ago - Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform - GlobeNewsWire
- 16 days ago - Plus Therapeutics reports NCCN Central Nervous System Cancers guidelines update - TheFly
- 16 days ago - Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Transcript: Investor update - Transcripts
- 4 weeks ago - Plus Therapeutics Press release: Investor update - Filings